Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Lizard King's Trading Swamp -- Ignore unavailable to you. Want to Upgrade?

To: TATRADER who wrote (5562)	3/30/1998 10:55:00 PM
From: majormember	Respond to of 7396

Mark, SNRS treats hyperopia (far-sighted) vs. VISX or BEAM excimer which treat myopia (near-sightedness). SNRS procedure use Holmium laser's which utilize a patented process that shrinks collagen, developed and patented by Dr. Bruce Sand (the "Sand Process"). Its patented Corneal Sparing LTK(tm) system is a non-contact application for correction of hyperopia, presbyopia (loss of focus due to aging), and OVERCORRECTION resulting from VISX/BEAM excimer; PRK and LASIK. VISX or BEAM CANNOT alter their technology to perform the same procedure as SNRS. The excimer laser takes tissue away from the cornea and the Holmium laser uses heat to shrink tissue around the edges; two entirely different procedures. No chance of patent infringement; though we hope to infringe on the patients they have overcorrected. As for patient regression, SNRS LTK procedure is stable for 2 years, is far superior and safer then the excimer PRK. The link below is an index of articles from Nov. 97 issue of Ophthalmology, the peer review journal of the American Academy: Message 2698376 Best wishes, Skane